The observed lower prevalence of RTK-RAS alterations in early-onset CRC compared to late-onset CRC is clinically significant, as it suggests that younger patients may harbor alternative oncogenic drivers not typically targeted by current standard-of-care therapies such as anti-EGFR agents. This evidence concerns the gene EGFR and colorectal carcinoma.